SGMO - BioMarin: Depressed Price Due To CRL Major Catalysts Ahead May, 31 2021 11:00 PM Sangamo Therapeutics Inc. BioMarin stock remains depressed since the August CRL. There are major catalysts ahead. BMRN has a solid cash balance and revenue stream. For further details see: BioMarin: Depressed Price Due To CRL, Major Catalysts Ahead